Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2016 -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter and year ended December 31, 2015, and provide a general business overview on Friday, February 26, 2016, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).
Conference Call Details
To access the live conference call, please dial (844) 452-6828 from the U.S. and Canada or +1(765) 507-2588 internationally, and use the passcode 48937755. Please dial in 10 minutes prior to the start of the call. To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company’s website at http://investors.portola.com. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. A replay of the webcast will be available on the Company’s website for 30 days following the live event.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success. These programs include betrixaban, an oral, once-daily Factor Xa inhibitor being evaluated in the APEX Phase 3 study for prophylaxis of venous thromboembolism; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart W2O Group [email protected]
